Compare GSK plc (GSK) vs Nike Inc (NKE) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Nike (NKE) trades at $42.86, down 2.06% today, with a bearish technical signal and recent earnings beats. Revenue declined to $46.31B in 2025, with net income margin at 6.7%. The stock shows strong profitability with ROE of 22.14% but faces headwinds in China and EMEA. Analysts maintain a consensus buy rating with a $50.80 price target, suggesting 18.5% upside.

Outlook remains cautious near-term due to sales pressure and margin compression, but long-term brand strength and digital DTC strategy offer recovery potential. Key risks include consumer demand softness and competitive pressures. The stock presents a contrarian opportunity if execution improves, supported by institutional confidence.